Comparative Pharmacology
Head-to-head clinical analysis: METADATE ER versus METHYLIN ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METADATE ER versus METHYLIN ER.
METADATE ER vs METHYLIN ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.
20-60 mg orally once daily in the morning
None Documented
None Documented
Terminal elimination half-life: 3-6 hours (mean 4.5 hours) for methylphenidate; clinical context: requires multiple daily dosing or extended-release formulation.
Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Renal (80% as metabolites, <1% unchanged); fecal (10-20%) via biliary elimination.
Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant